Lion’s mane as powder or capsules: what research shows about cognitive effects

Does it matter for memory and focus whether you take lion’s mane as a loose powder or in capsules? The format on its own tells you very little. What shapes the composition is mainly which part of the mushroom was used and how it was processed. Small studies point to cognitive improvements, especially in older adults. In healthy younger people the results are mixed. So far there is no evidence that any particular preparation works better.

In German, lion’s mane is called Igelstachelbart. It is sold as ground mushroom and as an extract, each available loose or in capsules. When you compare two products, the first step is to look at what is inside: what material was processed, and which compounds does the product contain?

What lion’s mane powder actually is

Lion’s mane powder is dried, powdered Hericium erinaceus. Quite different products are sold under that name, though: ground fruiting body, mycelium grown on grain, or a concentrated extract. The fruiting body is the visible mushroom; the mycelium is its network of threadlike filaments.

The main groups of bioactive compounds include hericenones in the fruiting body and erinacines in the mycelium. Beta-glucan polysaccharides make up a large share of the fiber in both. The amounts of these compounds can vary widely from one powder to the next.

Along with reishi, cordyceps and chaga, lion’s mane belongs to the so-called functional mushrooms. Research most often looks at its possible effects on cognitive function. The focus is mainly on a suspected influence on nerve growth factor (NGF), a protein that supports the survival and growth of nerve cells. One review covers the neurotrophic and neuroprotective effects of Hericium erinaceus, meaning possible growth-promoting and protective effects on nerve cells.

Hericenones, erinacines and beta-glucans: the main bioactive compounds

Preclinical work links hericenones to stimulated NGF synthesis. This fits with cell culture findings in which nerve cell projections grow more strongly. A foundational review describes the chemistry and bioactive compounds of fruiting bodies and mycelium.

Erinacines come from mycelial cultures. Researchers continue to identify new cyathane diterpenoids, including erinacine Z1 and Z2, which may stimulate the production of neurotrophins. These compounds are examined in work on new cyathane diterpenoids. The 2023 review and the 2025 review describe extracts enriched with erinacine A as having particularly strong neurotrophic activity. That activity, however, does not mean a superior clinical effect in humans.

Beta-glucan polysaccharides are soluble fibers. Their concentration depends heavily on the extraction method. Products made from mycelium grown on grain can contain erinacines, but also considerable amounts of starch from the substrate. Fruiting body powder contains hericenones and only small amounts of erinacines. So two powders with the same mushroom name on the label can have very different compositions.

From East Asian kitchens to the supplement shelf

Hericium erinaceus is native to East Asia, North America and Europe. In China, Japan and Korea the mushroom has long been used as food and in traditional medicine. It drew particular attention in the Western supplement market after a randomized Japanese study from 2009 reported cognitive improvements in older adults with mild cognitive impairment.

Commercial cultivation of mycelium on grain grew out of US farming operations. Fruiting body powder, by contrast, is more typical of Asian supply chains. How the bioactive profiles of fruiting bodies and mycelium differ is described in a foundational review of chemistry, nutrition and health-promoting properties.

How lion’s mane might support cognitive function

The leading candidate mechanism is an influence on the signaling pathways of NGF and BDNF (brain-derived neurotrophic factor). Hericenones and erinacines could be involved. Preclinical and early clinical work examines these pathways in connection with the growth of nerve cell projections and the function of synapses, the contact points between nerve cells. A review of the therapeutic potential in depressive disorders explains these lines of research.

NGF/BDNF stimulation and the growth of nerve cell projections

In cell culture studies, aqueous extracts of H. erinaceus promote the growth of nerve cell projections in neuroblastoma-glioma cells. These in vitro findings describe something that happens in the lab. They do not show whether a corresponding effect can be achieved in human tissue under clinical conditions.

Possible downstream processes under discussion include NGF-mediated growth of projections, signaling pathways that counter programmed cell death, and less oxidative stress in nerve tissue. The precise evidence for these mechanisms is still open. The same applies to the neuroprotective effects described for erinacine A-enriched mycelium extracts in animal models of Alzheimer’s pathology.

Early findings suggest that some of these mechanisms can be reproduced in preclinical models. Whether they carry over to humans remains open. A randomized controlled trial in healthy young adults found neither metabolic nor cognitive effects after four weeks. How far marketing claims can run ahead of clinical data is illustrated by a critical assessment of lion’s mane claims in connection with ALS.

Bioavailability and the extraction question

How much of the hericenones and erinacines taken by mouth the human body absorbs has not yet been well described. Most data on absorption, distribution and breakdown come from preclinical studies.

Beta-glucan polysaccharides are mostly fermented by the gut microbiota. This is what the occasionally advertised prebiotic properties of lion’s mane refer to. A review of beta-glucans covers their bioavailability and biological properties.

Raw mushroom powder contains chitin, which is hard to digest. Hot water extraction releases water-soluble compounds. A dual process using hot water and alcohol is meant to also capture lipophilic (fat-soluble) compounds such as erinacines and so deliver a broader range of substances. Whether this process improves absorption or effect in humans is unresolved. A broader range of compounds does not, on its own, demonstrate greater clinical benefit. The review of extraction deals with polysaccharides.

For composition, then, the extraction method tells you more than whether the product comes in a capsule or a powder pouch. In most studies, lion’s mane was taken with food. There are only limited data on the best time of day to take it in humans.

How solid are the claims about lion’s mane and cognition?

There are still few randomized controlled trials in humans, but their number is growing. Several provide positive signals. At least one study rated as well designed, however, found no effect. Making sense of these results means looking at the populations studied, the preparations used and the outcomes measured together.

The evidence ratings below are meant as provisional guidance; they have not been independently checked. The terms are used here as follows:

• “Strong” requires at least two well-designed randomized controlled trials with a clinically relevant endpoint and a consistent direction of effect.
• “Moderate” means one such trial, or several smaller studies with mixed results.
• “Limited” applies when there are only small, short or methodologically weak human studies.
• “Animal data / preclinical only” means that no completed human studies exist.
• “Anecdotal” means that no controlled evidence is available.

Cognitive function in older adults with mild cognitive impairment: moderate

The most frequently cited human study is a double-blind, placebo-controlled randomized trial in adults aged 50–80 with mild cognitive impairment. Participants took 3 g of Yamabushitake powder daily for 16 weeks. A composite cognitive test score improved by a statistically significant margin. The sample, however, was small.

A second double-blind randomized trial in healthy older adults also reported cognitive improvements. It points in the same direction, but studied a different group. Both studies had small samples drawn from a geographically narrow setting. Among the results discussed here, the signal of cognitive improvement in older adults is considered the most reproducible finding.

Cognitive function in healthy young or middle-aged adults: limited

A small double-blind randomized pilot study in healthy young adults suggests that supplementation might improve the speed of cognitive performance and reduce subjective stress. A more recent randomized trial using a standardized extract in healthy adults adds to the data for younger adults.

Another randomized trial found no detectable cognitive effect after four weeks. Taken together, these studies do not yet form a consistent picture; the evidence for this group remains limited.

Mood and depressive symptoms: limited

A review of H. erinaceus and depressive disorders describes neurotrophic and neurogenic mechanisms that could be relevant to mood. A review of mushroom consumption and neurocognitive health also found some signs of mood-related effects.

Randomized controlled human trials that specifically examine mood as the primary endpoint are still rare. Lion’s mane might be associated with changes in mood. These signals do not support its effectiveness as a treatment for depression.

Neuroprotection and disease processes relevant to Alzheimer’s: preclinical findings and one small human study

A small pilot study of erinacine A-enriched mycelium in early Alzheimer’s disease provides exploratory results, but no conclusive proof of efficacy. Classifying this area of research as “animal data / preclinical only” is therefore contradictory.

More recent narrative reviews of neuroprotective properties and erinacine A-enriched extracts and of lion’s mane as a whole cover the broader preclinical research field. Such effects have been observed repeatedly in animal models. In humans, neither prevention of Alzheimer’s nor a slowing of disease progression has been demonstrated so far. Lion’s mane is not a proven treatment for Alzheimer’s disease.

Support in ALS: anecdotal

A critical assessment of lion’s mane claims in connection with ALS concludes that such marketing claims are not supported by clinical evidence. That assessment does not cite any controlled human study supporting use in ALS. “Anecdotal” here refers to the absence of clinical proof of efficacy.

It has not been shown that lion’s mane:

• treats, prevents or reverses Alzheimer’s, ALS, dementia or other neurological diseases;
• raises NGF or BDNF in the human brain after oral supplementation, as demonstrated by imaging;
• can replace a medical evaluation of persistent cognitive complaints;
• delivers consistent cognitive benefits in healthy young adults across different studies.

Powder, hot water extract or dual extract: what role does the fruiting body play?

When comparing products, what matters most is the mushroom tissue and the extraction method. Powder and capsules can have the same contents. Two powders, on the other hand, can differ considerably, for example if one is ground fruiting body and the other is a mycelium extract.

The amounts below describe dose ranges that have been cited. They are not individually checked intake recommendations, and how exactly they map onto specific studies and products is still open.

• Raw fruiting body powder is dried, ground mushroom containing beta-glucans, hericenones and hard-to-digest chitin. The typical study dose given is 1–3 g daily; the 2009 Yamabushitake study used 3 g daily. The certificate of analysis (COA) should say “fruiting body.” Provenance includes information on the growing region and the age at harvest.
• Hot water extract from the fruiting body is meant to concentrate water-soluble beta-glucans and hericenones; some of the chitin is removed. Whether hericenones are correctly classified as water-soluble here is unresolved. The typical dose given is 500 mg to 1 g daily. A stated beta-glucan content makes comparison easier. The suggested floor of 25 % or more, however, is an editorial judgment and not a clinically validated minimum standard. USP, NSF and ConsumerLab are named as the preferred independent testing services.
• Dual extract is made with hot water and alcohol. The process is meant to capture water-soluble substances such as beta-glucans as well as lipophilic substances such as erinacines from mycelium. Hericenones from fruiting bodies are also counted among the water-soluble substances here, which is still unresolved. Whether such a product really contains the broadest range of compounds cannot be adequately supported by the review of polysaccharides. The typical dose given is 500 mg to 1 g daily. A meaningful COA documents the dual process, including the alcohol extraction step.
• Powder from mycelium grown on grain is made by drying and grinding the mycelium together with its substrate, often oats or rice. It can contain erinacines, but also a lot of starch from the grain. This can lower the share of active ingredients. The bioactive profiles and the metabolite profiles of mycelium and fruiting bodies differ markedly. The ratio of mycelium to grain therefore belongs on the COA. The word “mushroom” on its own does not tell you whether the contents are mostly grain.

A meaningful COA states the source tissue, the beta-glucan content and the extraction method. Independent product testing can help put these details into context. In the selection used so far, USP, NSF International and ConsumerLab are considered the most accessible services for US consumers.

For fruiting body products, standardization to beta-glucans is suggested as a practical indirect quality marker. For mycelium-on-grain products, the ratio of mycelium to grain also matters, and it is often missing from consumer labels. A comparison of metabolites describes the differences between these materials. Because their chemistry differs, study results cannot simply be transferred from one product to another.

Lion’s mane powder under the US DSHEA law: status as of May 2026

In the United States, lion’s mane is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). The classification described here, which has not yet been independently checked, refers to May 2026: according to it, lion’s mane is not approved by the US Food and Drug Administration (FDA) for any indication. Nor, on this account, is there any FDA-authorized health claim relating to cognition, NGF or BDNF modulation, mood or neurological support.

Marketing claims that lion’s mane treats, prevents or cures Alzheimer’s, ALS, depression or dementia can lead to a product being considered an unapproved drug under FDA definitions. There are also reports of FDA warning letters over such claims in the wider market for functional mushrooms and herbal supplements. A treatment promise on a label is therefore a regulatory red flag. It is not evidence of effectiveness.

As of the date given, lion’s mane is neither on the prohibited list of the World Anti-Doping Agency (WADA) nor classified as a controlled substance. This status can change. Before taking part in sports competitions, check the current classification with the FDA and WADA. The US information does not describe the current legal situation in Germany or other countries.

Lion’s mane safety: watching for allergic and skin reactions

Overall, the preclinical and clinical studies discussed here describe a favorable safety profile. No serious adverse events were reported in the human studies at the doses tested. These studies, however, were small and short. They cannot fully assess rare or longer-term risks; allergic reactions and skin reactions in particular deserve attention.

Reported side effects

Adverse events in human studies were rare and mostly mild. The most commonly reported were nausea, bloating and loose stools. Case reports also document skin and allergic reactions, including contact dermatitis and respiratory symptoms in people sensitive to mushrooms.

A toxicology study of a beta-glucan extract from H. erinaceus found a safety profile rated as favorable at doses considered relevant for supplements. A 28-day oral feeding study in rats found no significant toxicological abnormalities at doses classified the same way. A subchronic study in rodents with hematological, biochemical and histopathological assessment also produced reassuring results.

A more recent toxicological assessment of mushroom powders adds data on the powder form. Each of these results applies to specific preparations under controlled conditions. They cannot be read as proof of safety for all people, products or doses.

Drug interactions

• With anticoagulants and antiplatelet drugs such as warfarin or clopidogrel, there is a theoretical risk of interaction. This is based on an inhibition of platelet activity described in preclinical work. The data discussed here do not mention documented interactions in humans; clinically relevant interaction data are sparse. If you take such medication, the possible risk should still be taken into account.
• With diabetes medications such as insulin and sulfonylureas, an additional drop in blood sugar, up to and including hypoglycemia, is conceivable. This assumption rests on animal data on blood sugar-lowering effects. Data on interactions in humans are lacking.
• With immunomodulating drugs, an interaction is theoretically possible because beta-glucans interact with signaling pathways of the innate immune system. Clinical interactions with immunosuppressants or immunomodulators have not been characterized in humans.

Pregnancy, breastfeeding and special groups

There are no controlled human studies of lion’s mane supplementation during pregnancy. For that reason, it is generally avoided during this time. The same caution applies to breastfeeding. The reason is the lack of safety data; this does not mean harm has been shown.

Known allergies to edible or other mushrooms are listed as a contraindication. Documented cross-reactions with other fungi have also been described. If you have such allergies, you need to talk to a doctor before taking it. There are no safety data on lion’s mane at supplement doses in children.

Who should avoid lion’s mane powder

In certain situations, whether lion’s mane is suitable has to be clarified before supplementing. These include contraindications, possible interactions and unclear product information. The following list is not exhaustive:

• Pregnancy and breastfeeding, because controlled human safety data at supplement doses are lacking.
• A known allergy to edible or other mushrooms.
• Taking anticoagulants or antiplatelet drugs without medical supervision of the additional supplement.
• Diagnosed cognitive disorders where lion’s mane is meant to replace a clinical evaluation.
• A product whose fruiting body content cannot be traced on the COA. The review of fruiting bodies and mycelium describes different materials; these differences alone do not show that any product is mislabeled.
• Childhood, since supplement doses have not been characterized in pediatric populations.

If any of these points applies, taking it should only be considered after talking to a doctor. A complete medication list and relevant lab values matter for that assessment.

Lion’s mane powder, hot water extract and dual extract compared

Does a product match a particular study result? For that, the starting material and the processing have to match. A mechanism under study can explain why researchers chose a preparation. Whether it leads to an everyday benefit has to be shown by studies in humans.

• Starting material and chemistry: Raw powder consists of dried, ground fruiting body or of mycelium including its grain substrate. Hot water extracts are meant to concentrate beta-glucans and water-soluble hericenones, although the classification of hericenones is unresolved. Dual extracts are meant to use hot water and alcohol to capture both water-soluble and lipophilic compounds, including erinacines. The review of polysaccharides does not adequately answer these further questions.
• Bioavailability: Chitin is described as a possible limiting factor for absorption from raw powder. Hot water extracts are said to make water-soluble compounds more available; dual extracts are credited with the best access to water- and alcohol-soluble compound groups. Because data on absorption in humans are limited, this ranking is not clinically established.
• Strongest human evidence: For raw powder, there is the 2009 study using 3 g of Yamabushitake powder daily in older adults with mild cognitive impairment. For assessing hot water and dual extracts, the 2019 study showing cognitive improvements in healthy older adults, the 2023 study showing faster cognitive performance and less stress in young adults and the 2025 study using a standardized extract in healthy adults are drawn on. As long as their preparation types have not been clearly established, they do not allow a reliable comparison of extraction methods. For erinacine A-enriched mycelium extracts, there is the small 2020 pilot study in early Alzheimer’s disease. A 2025 review describes this type of extract as having particularly strong neurotrophic activity. That does not show clinical superiority.
• Dose ranges studied: 1–3 g daily is given for raw powder, 500 mg to 1 g daily for hot water extract, and likewise 500 mg to 1 g daily for dual extract. For mycelium on grain the figures vary, because the substrate dilutes the concentration of active compounds. These ranges are not personal intake recommendations.
• Key safety differences: All forms are described as having a broadly similar profile, with rare allergic and skin reactions. Whether their side effect profiles really are the same, however, has not been established. With mycelium on grain, exposure to grain allergens is also possible. The COA should therefore name the substrate.
• Relative cost: Raw powder: $. Hot water extract: $$. Dual extract: $$$. Mycelium on grain: $–$$. The dollar signs indicate relative price tiers, not actual prices.
• Regulatory status: All forms are sold in the US as dietary supplements under DSHEA. According to the regulatory classification described here, which has not yet been checked, no form has FDA-authorized health claims.

For the signals of cognitive improvement in older adults with mild cognitive impairment (MCI), the 2009 study is especially relevant. Whether fruiting body powder is, overall, the form most often studied repeatedly in human trials remains open while the attribution of the preparations is unresolved. The claim that a dual mycelium extract offers the broadest spectrum of active compounds for the neurotrophic erinacine A mechanism is also not established. In any case, such a spectrum would not support either a better effect in humans or the interchangeability of different preparations.

Mycelium and fruiting body extracts have markedly different bioactive profiles. A review of erinacine-enriched mycelium explains this line of research. If you have cognitive complaints, it can make sense to first look into possible causes. Depending on the situation, lab values such as TSH, vitamin B12, vitamin D and ferritin may come into question.

Which blood tests may be useful before lion’s mane

Lab tests can help identify possible causes of persistent cognitive complaints. Which values make sense depends on the symptoms, the medical history and the doctor’s judgment. No plasma test for hericenones or the NGF response in routine clinical use is described here.

• TSH (thyroid-stimulating hormone) helps assess thyroid function. Both an underactive and an overactive thyroid can come with “brain fog,” fatigue and changes in concentration. Ruling out a thyroid disorder is considered a usual first step in a cognitive evaluation.
• Free T4 complements TSH in assessing thyroid hormone status. Whether a TSH value in the upper normal range, together with persistent cognitive complaints, already justifies testing it is not settled here.
• Vitamin B12 is relevant because a deficiency is a well-described, potentially reversible cause of cognitive symptoms. Older adults, people on a vegan diet and people taking metformin or proton pump inhibitors long term are at particular risk.
• Vitamin D: Low levels are associated with cognitive symptoms in observational data. That does not establish a clear cause-and-effect relationship. How common insufficient levels are is put forward as an argument for a baseline measurement, but on its own it does not justify routine testing. Whether such testing makes sense has not been examined here.
• Ferritin helps estimate iron stores. Low levels can come with fatigue and concentration problems even before a blood count shows marked anemia.

When cognitive complaints persist, looking into possible causes gives a more reliable basis for further decisions. Without it, it may stay unclear which factors explain the complaints or any later changes. A doctor can judge whether a nutrition-related cause, a thyroid disorder or something else is in play. None of this adds up to a general test panel before taking lion’s mane.

When cognitive complaints should be checked by a doctor

Persistent cognitive complaints, suspected early symptoms of dementia, or chronically low mood deserve a medical evaluation. A visit to your primary care doctor is an appropriate starting point. Depending on the situation, the lab values described above may be part of it.

The evaluation helps identify possible causes and decide on suitable next steps. It remains important even if lion’s mane is later considered as a supplement.

Frequently asked questions

What is the difference between lion’s mane powder and capsules?

With the same starting material, the same extract quality and an equivalent dose, loose powder and capsules can contain comparable amounts of hericenones, erinacines and beta-glucans. In that case they differ mainly in how easy they are to handle and to dose.

What matters more for composition is whether a hot water extract or a dual extract was used, and whether the product is made from fruiting bodies or from mycelium grown on grain. The review of fruiting bodies and mycelium and the review of erinacine-enriched mycelium cover these differences.

Does lion’s mane powder actually improve cognitive function?

Limited data point to possible improvements in older adults with mild cognitive impairment. These results cannot be carried over to healthy younger adults. Changes are described over 4–16 weeks, with the study in mild cognitive impairment as the reference. According to the available information, some studies were industry-funded. Possible bias should therefore be taken into account when weighing them.

What doses of lion’s mane have been used in studies?

In the 2009 study, adults with mild cognitive impairment received 3 g of dried Yamabushitake powder daily for 16 weeks. The exact age range is still unresolved.

With reference to the 2019 study, comparable doses are described in similar populations. In younger healthy adults, more recent studies have tended to use standardized extracts, including the 2023 pilot study. How closely the preparations and doses can be compared remains open. Research doses are not individual intake recommendations.

What are the side effects of lion’s mane powder?

In the human studies described, adverse events were rare and mostly mild. Gastrointestinal complaints were the most common. Case reports also document rare allergic and skin reactions.

Toxicology studies in rodents and a 2025 toxicological assessment of mushroom powders showed, according to the assessment so far, no major safety signals at doses considered relevant for supplements. These data do not rule out individual risks or rare serious reactions.

Is lion’s mane powder approved by the FDA?

According to the regulatory classification described here as of May 2026, which has not been independently checked, lion’s mane powder is not approved by the FDA for any indication, including support of cognitive function. It is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). Under that law, no FDA approval is required before marketing.

Product claims are therefore not proof of effectiveness. The 2024 assessment of lion’s mane claims related to ALS deals with the gap between such claims and the scientific evidence.

What is the difference between lion’s mane powder and an extract?

Raw lion’s mane powder is ground mushroom and contains, among other things, hard-to-digest chitin and beta-glucans. How large their share is in a given product cannot be determined from this. Extracts are made with hot water or a dual process to concentrate certain bioactive compounds.

Fruiting body products are described as richer in hericenones than mycelium-on-grain products. In the latter, considerable amounts of starch can reduce the share of other ingredients. A review of fruiting bodies and mycelium explains the different profiles. Dual extracts are meant to deliver a broader range of compounds than raw powder or simple extracts. Whether both hericenones and erinacines are concentrated in the process, as claimed, is not adequately settled by the source on polysaccharides. Composition and suitability also depend on the starting material.

Who should avoid lion’s mane powder?

People who are pregnant or breastfeeding should not take it as a supplement, because controlled human studies are lacking. If you take anticoagulants or diabetes medication, you need to talk to a doctor first. Preclinical research suggests possible interactions with blood clotting and blood sugar regulation; clinical interactions have not yet been demonstrated.

Which blood values may be useful before taking lion’s mane?

TSH, free T4, vitamin B12, vitamin D and ferritin may be considered when evaluating cognitive complaints. They do not, however, form a general test panel to run before lion’s mane. Whether all of these values should routinely be part of a primary care cognitive evaluation has not been clinically settled here.

Which tests make sense, and whether a mushroom supplement could play any role at all, depends on the symptoms, risk factors and medical history. These questions can be sorted out in a conversation with a doctor.

References and sources

1. Szućko-Kociuba I, Trzeciak-Ryczek A, Kupnicka P, Chlubek D (2023). Neurotrophic and Neuroprotective Effects of Hericium erinaceus. International journal of molecular sciences, 24(21). https://doi.org/10.3390/ijms242115960
   PubMed: https://pubmed.ncbi.nlm.nih.gov/37958943/

2. Rupcic Z, Rascher M, Kanaki S, Köster RW, Stadler M, Wittstein K (2018). Two New Cyathane Diterpenoids from Mycelial Cultures of the Medicinal Mushroom Hericium erinaceus and the Rare Species, Hericium flagellum. International journal of molecular sciences, 19(3). https://doi.org/10.3390/ijms19030740
   PubMed: https://pubmed.ncbi.nlm.nih.gov/29509661/

3. Cornford N, Charnley M (2025). Nutrition research reviews, 38(2), 613-627. https://doi.org/10.1017/S0954422425000058
   PubMed link from the source text: https://pubmed.ncbi.nlm.nih.gov/39988819/

4. Wang XY, Zhang DD, Yin JY, Nie SP, Xie MY (2019). Recent developments in Hericium erinaceus polysaccharides: extraction, purification, structural characteristics and biological activities. Critical reviews in food science and nutrition, 59(sup1), S96-S115. https://doi.org/10.1080/10408398.2018.1521370
   PubMed: https://pubmed.ncbi.nlm.nih.gov/30421988/

5. Friedman M (2015). Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion’s Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds. Journal of agricultural and food chemistry, 63(32), 7108-23. https://doi.org/10.1021/acs.jafc.5b02914
   PubMed: https://pubmed.ncbi.nlm.nih.gov/26244378/

6. Chong PS, Fung ML, Wong KH, Lim LW (2019). Therapeutic Potential of Hericium erinaceus for Depressive Disorder. International journal of molecular sciences, 21(1). https://doi.org/10.3390/ijms21010163
   PubMed: https://pubmed.ncbi.nlm.nih.gov/31881712/

7. Lai PL, Naidu M, Sabaratnam V, Wong KH, David RP, Kuppusamy UR, Abdullah N, Malek SN (2013). Neurotrophic properties of the Lion’s mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia. International journal of medicinal mushrooms, 15(6), 539-54. https://doi.org/10.1615/intjmedmushr.v15.i6.30
   PubMed: https://pubmed.ncbi.nlm.nih.gov/24266378/

8. Brandalise F, Roda E, Ratto D, Goppa L, Gargano ML, Cirlincione F, Priori EC, Venuti MT, Pastorelli E, Savino E, Rossi P (2023). Journal of fungi (Basel, Switzerland), 9(5). https://doi.org/10.3390/jof9050551
   PubMed link from the source text: https://pubmed.ncbi.nlm.nih.gov/37233262/

9. Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, Chen YW, Chen YP, Chen CC, Lin DP (2020). Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched. Frontiers in aging neuroscience, 12, 155. https://doi.org/10.3389/fnagi.2020.00155
   PubMed: https://pubmed.ncbi.nlm.nih.gov/32581767/

10. Grozier CD, Alves VA, Killen LG, Simpson JD, O’Neal EK, Waldman HS (2022). Four Weeks of Hericium erinaceus Supplementation Does Not Impact Markers of Metabolic Flexibility or Cognition. International journal of exercise science, 15(2), 1366-1380. https://doi.org/10.70252/XZKO8571
    PubMed: https://pubmed.ncbi.nlm.nih.gov/36582308/

11. Muhanna M, Lund I, Bromberg M, Wicks P, Benatar M, Barnes B, Pierce K, Ratner D, Brown A, Bertorini T, Barkhaus P, Carter G, Mascias Cadavid J, McDermott C, Glass JD, Pattee G, Armon C, Bedlack R, Li X (2024). ALSUntangled #73: Lion’s Mane. Amyotrophic lateral sclerosis & frontotemporal degeneration, 25(3-4), 420-423. https://doi.org/10.1080/21678421.2023.2296557
    PubMed: https://pubmed.ncbi.nlm.nih.gov/38141002/

12. Singla A, Gupta OP, Sagwal V, Kumar A, Patwa N, Mohan N, Ankush, Kumar D, Vir O, Singh J, Kumar L, Lal C, Singh G (2024). Beta-Glucan as a Soluble Dietary Fiber Source: Origins, Biosynthesis, Extraction, Purification, Structural Characteristics, Bioavailability, Biofunctional Attributes, Industrial Utilization, and Global Trade. Nutrients, 16(6). https://doi.org/10.3390/nu16060900
    PubMed: https://pubmed.ncbi.nlm.nih.gov/38542811/

13. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy research : PTR, 23(3), 367-72. https://doi.org/10.1002/ptr.2634
    PubMed: https://pubmed.ncbi.nlm.nih.gov/18844328/

14. Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical research (Tokyo, Japan), 40(4), 125-131. https://doi.org/10.2220/biomedres.40.125
    PubMed: https://pubmed.ncbi.nlm.nih.gov/31413233/

15. Docherty S, Doughty FL, Smith EF (2023). The Acute and Chronic Effects of Lion’s Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients, 15(22). https://doi.org/10.3390/nu15224842
    PubMed: https://pubmed.ncbi.nlm.nih.gov/38004235/

16. Surendran G, Saye J, Binti Mohd Jalil S, Spreadborough J, Duong K, Shatwan IM, Lilley D, Heinrich M, Dodd GF, Surendran S (2025). Acute effects of a standardised extract of Hericium erinaceus (Lion’s Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in nutrition, 12, 1405796. https://doi.org/10.3389/fnut.2025.1405796
    PubMed: https://pubmed.ncbi.nlm.nih.gov/40276537/

17. Cha S, Bell L, Shukitt-Hale B, Williams CM (2024). A review of the effects of mushrooms on mood and neurocognitive health across the lifespan. Neuroscience and biobehavioral reviews, 158, 105548. https://doi.org/10.1016/j.neubiorev.2024.105548
    PubMed: https://pubmed.ncbi.nlm.nih.gov/38246232/

18. Contato AG, Conte-Junior CA (2025). Lion’s Mane Mushroom. Nutrients, 17(8). https://doi.org/10.3390/nu17081307
    PubMed: https://pubmed.ncbi.nlm.nih.gov/40284172/

19. Berger RG, Bordewick S, Krahe NK, Ersoy F (2022). Mycelium vs. Fruiting Bodies of Edible Fungi-A Comparison of Metabolites. Microorganisms, 10(7). https://doi.org/10.3390/microorganisms10071379
    PubMed: https://pubmed.ncbi.nlm.nih.gov/35889098/

20. U.S. Food and Drug Administration. (n.d.). U.S. Food and Drug Administration. https://fda.gov
    Also linked in the source text: http://fda.gov

21. World Anti-Doping Agency. (n.d.). World Anti-Doping Agency. https://wada-ama.org
    Also linked in the source text: http://wada-ama.org

22. Chen SN, Chang CS, Yang MF, Chen S, Soni M, Mahadevan B (2022). Subchronic toxicity and genotoxicity studies of Hericium erinaceus β-glucan extract preparation. Current research in toxicology, 3, 100068. https://doi.org/10.1016/j.crtox.2022.100068
    PubMed: https://pubmed.ncbi.nlm.nih.gov/35341120/

23. Li IC, Chen YL, Lee LY, Chen WP, Tsai YT, Chen CC, Chen CS (2014). Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 70, 61-7. https://doi.org/10.1016/j.fct.2014.04.040
    PubMed: https://pubmed.ncbi.nlm.nih.gov/24810469/

24. Lakshmanan H, Raman J, David P, Wong KH, Naidu M, Sabaratnam V (2016). Haematological, biochemical and histopathological aspects of Hericium erinaceus ingestion in a rodent model: A sub-chronic toxicological assessment. Journal of ethnopharmacology, 194, 1051-1059. https://doi.org/10.1016/j.jep.2016.10.084
    PubMed: https://pubmed.ncbi.nlm.nih.gov/27816657/

25. Mahadevan K, Daoust J, Brendler T, Chaudhary A, Saifi A, Garg VK (2025). A toxicological assessment of Hericium erinaceus (Lion’s mane) and Trametes versicolor (Turkey tail) mushroom powders. Frontiers in toxicology, 7, 1651442. https://doi.org/10.3389/ftox.2025.1651442
    PubMed: https://pubmed.ncbi.nlm.nih.gov/41230556/

26. Li IC, Lee LY, Tzeng TT, Chen WP, Chen YP, Shiao YJ, Chen CC (2018). Neurohealth Properties ofHericium erinaceusMycelia Enriched with Erinacines. Behavioural neurology, 2018, 5802634. https://doi.org/10.1155/2018/5802634
    PubMed: https://pubmed.ncbi.nlm.nih.gov/29951133/

Sources

• U.S. Food and Drug Administration. (n.d.). U.S. Food and Drug Administration. https://fda.gov
• World Anti-Doping Agency. (n.d.). World Anti-Doping Agency. https://wada-ama.org